Bio-logic Receives FDA Clearance for EEG System

Bio-logic Systems Corp. announced that it has received FDA clearance for its new Ceegraph 128 System. The new electroencephalography system provides more recording sites than the 32 channel Ceegraph SE and is positioned to compete in the $20 million, long-term epilepsy monitoring market. The 128 channel system utilizes Ceegraph's single integrated solution for routine EEG, Epilepsy Monitoring and Ambulatory Recording, all on one expandable system with a uniform user interface, unique expandability options and flexibility in configuration.

The Ceegraph 128, manufactured by Bio-logic, will be launched in April, 1998 at the American Academy of Neurology Meeting. In addition to providing more recording sites, the Ceegraph 128 employs Smart-Pack, Bio-logic's patented, loss less data compression technology.

The Ceegraph 128 records electrical activity in the brain at up to 128 sites to diagnose conditions such as epilepsy as well as monitoring the progress of neurological disorders and/or treatments of neurological conditions. The Ceegraph 128 can be upgraded to include digital video recording, that is synchronized with the EEG. The synchronized recording captures both a visual and electrical record of seizure activity. The patient recording can then be read on a standard Ceegraph Reader Station. Bio-logic's optional Smart Track Spike and Seizure Detection program, developed in collaboration with Johns Hopkins Epilepsy Center, speeds the reading process by providing computer assisted analysis of epileptic spikes/seizures.

Bio-logic Systems Corp., headquartered in Mundelein, Illinois., designs, develops, assembles and markets computer-based electro-diagnostic systems for use by hospitals, clinics, universities and physicians.

Edited By Patricia Breen